Company Overview
Company Type: Public Company
Website: www.milestonepharma.com
Number of Employees: 39
Ticker: MIST (NasdaqGS)
Year Founded: 2003


Business Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
8.2
Market Capitalization
171.7
TEV/Total Revenue
14.8x
EBITDA
(82.5)
Total Enterprise Value
121.0
TEV/EBITDA
NM
EBIT
(82.6)
Cash & ST Invst.
119.1
P/Diluted EPS Before Extra
NM
Net Income
(79.9)
Total Debt
68.4
Price/Tang BV
3.1x
Capital Expenditure
(0.4)
Total Assets
132.0
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.53)
(0.59)
(2.09)
(3.15)
(2.65)
Revenue (mm)
0.00
0.00
1.36
18.33
0.00
EBITDA (mm)
(22.85)
(23.39)
(89.77)
(63.11)
(76.44)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
91.99x
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Outperform (1.80)
Target Price
18.77
Potential Upside
358.47%


Key Professionals
Name
Title
Oliveto, Joseph G.
CEO, President & Director
Douville, Philippe 
Founder, Strategic Advisor & Member of Scientific Advisory Board
Hasija, Amit 
CFO & Executive VP of Corporate Development
Nelson, Jeff 
Chief Operating Officer
Fox, Kim 
Vice President of Communications
Girglani, Roshan 
Vice President of Marketing
Bharucha, David B.
Chief Medical Officer
Holz, Anita 
VP & Head of Medical Affairs
Rousseau, Guy 
SVP of Regulatory Affairs and Quality Management
Sager, Philip T.
Chief Medical Advisor & Member of the Scientific Advisory Board

Key Board Members
Name
Title
Wills, Robert James
Independent Chairman of the Board
Oliveto, Joseph G.
CEO, President & Director
Douville, Philippe 
Founder, Strategic Advisor & Member of Scientific Advisory Board
Sager, Philip T.
Chief Medical Advisor & Member of the Scientific Advisory Board
Liebert, Debra K.
Independent Non-Executive Director
Tomsicek, Michael John
Independent Non-Executive Director
Camm, John 
Member of the Scientific Advisory Board
DiMarco, John
Member of the Scientific Advisory Board
Dorian, Paul 
Member of the Scientific Advisory Board
Fischer, Seth H. Z.
Independent Non-Executive Director
Giles, Lisa M.
Independent Non-Executive Director
Kopelman, Harry A.
Member of the Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
1111 Dr. Frederik-Philips Boulevard Suite 420 | Montreal, QC | H4M 2X6 | Canada
Phone: 514 336 0444   

Current and Pending Investors
Amplitude Ventures, BDC Capital Inc., Boxer Capital LLC, Domain Associates, L.L.C., Fonds de solidarité FTQ, Inovia Capital, Inc., Novo Holdings A/S, RTW Investments, LP, T. Rowe Price Associates, Inc., Tekla Capital Management LLC (Daniel Omstead), VR Adviser, LLC

Prior Investors
CQVB, Investment Arm, Fonds Bio-Innovation, Forbion Capital Partners B.V., Pappas Capital, LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 4.09
Market Cap (mm)
175.8
Open
 4.22
Shares Out. (mm)
42.9
Previous Close
 4.09
Float %
63.8%
Change on Day
0.10
Shares Sold Short (mm)
0.4
Change % on Day
2.4%
Dividend Yield %
-
Day High/Low
 4.22/ 3.95
Diluted EPS Excl. Extra Items
(1.87)
52 wk High/Low
 12.92/ 3.65
P/Diluted EPS Before Extra
NM
Volume (mm)
0.07
Avg 3M Dly Vlm (mm)
0.10
Beta 5Y
1.80


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)


Index Membership
S&P Americas Under USD3 Billion Index;S&P Americas BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Under USD2 Billion Index;S&P Americas BMI Growth Index;S&P Americas SmallCap Health Care (Sector) Index;S&P Americas Under USD1 Billion Index;S&P Canada SmallCap Index;S&P Canada SmallCap Growth Index;S&P Canada SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas SmallCap Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas Under USD1.2 Billion Index;S&P Canada BMI Growth Index;S&P Americas SmallCap Growth Index;S&P Americas Under USD1.5 Billion Index;S&P Canada Under USD2 Billion Index;S&P Americas SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P DM Ex-Australia SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada SmallCap Health Care (Sector) Index;S&P Canada Under USD3 Billion Index;S&P Canada BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia Under USD1 Billion Index;S&P Developed Ex-Australia Under USD1.2 Billion Index;S&P Developed Ex-Europe BMI Growth Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Health Care (Sector) Index;S&P Developed BMI Index;S&P Developed Ex-Asia-Pacific BMI Growth Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Eurozone BMI Growth Index;S&P Developed Ex-Eurozone SmallCap Index;S&P Developed Ex-Eurozone SmallCap Health Care (Sector) Index;S&P Developed BMI Growth Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Australia Under USD3 Billion Index;S&P Developed Ex-Europe BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Growth Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland SmallCap Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Switzerland Under USD1 Billion Index;S&P Developed Ex-Switzerland Under USD3 Billion Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Index;S&P Developed Ex-Asia-Pacific SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone Under USD1.5 Billion Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Under USD2 Billion Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan Under USD2 Billion Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Switzerland Under USD2 Billion Index;S&P Developed Ex-Europe SmallCap Index;S&P Developed Ex-Europe Under USD1 Billion Index;S&P Developed Ex-Europe Under USD1.5 Billion Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone Under USD1 Billion Index;S&P Developed Ex-Asia-Pacific Under USD1.2 Billion Index;S&P Developed Ex-Asia-Pacific Under USD3 Billion Index;S&P Developed Ex-Australia BMI Growth Index;S&P Developed Ex-Australia BMI Growth Health Care (Sector) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Growth Index;S&P DM Ex-U.S. & Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan Under USD1 Billion Index;S&P Developed Ex-Japan Under USD1.2 Billion Index;S&P Developed Ex-U.K. BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-U.K. Under USD1 Billion Index;S&P Developed Ex-U.K. Under USD1.2 Billion Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Index;S&P Developed Ex-U.S. & Japan SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. Under USD1.2 Billion Index;S&P Developed Ex-U.S. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD3 Billion Index;S&P Developed Ex-U.S. & Japan Under USD1.2 Billion Index;S&P Developed Ex-U.S. & Japan Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan Under USD2 Billion Index;S&P Developed Ex-U.S. & U.K. BMI Index;S&P Developed Ex-U.S. & U.K. BMI Growth Index;S&P Developed Ex-U.S. & U.K. SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. Under USD3 Billion Index;S&P Developed Ex-U.S. BMI Growth Health Care (Sector) Index;S&P Developed Under USD1.2 Billion Index;S&P Developed Under USD3 Billion Index;S&P Developed Ex-U.S. SmallCap Health Care (Sector) Index;S&P Developed SmallCap Index;S&P Developed Ex-Eurozone SmallCap Growth Index;S&P DM Ex-Eurozone SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan SmallCap Health Care (Sector) Index;S&P DM Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Canada BMI Growth Health Care (Sector) Index;S&P Canada Under USD1.2 Billion Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. SmallCap Index;S&P Developed Ex-U.K. Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan BMI Index;S&P Developed Ex-U.S. & Japan BMI Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan BMI Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Growth Index;S&P Developed Ex-U.K. SmallCap Health Care (Sector) Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Index;S&P Developed Ex-Europe Under USD1.2 Billion Index;S&P Developed Ex-Eurozone BMI Growth Health Care (Sector) Index;S&P Developed Ex-Eurozone Under USD1.2 Billion Index;S&P Developed Ex-Eurozone Under USD2 Billion Index;S&P Developed Ex-Eurozone Under USD3 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Index;S&P Developed Ex-U.S. & U.K. Under USD1.5 Billion Index;S&P Developed Ex-U.S. BMI Growth Index;S&P Developed Ex-U.S. & U.K. BMI Growth Health Care (Sector) Index;S&P DM Ex-U.S. & U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & U.K. SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. & U.K. Under USD1 Billion Index;S&P Developed Ex-U.S. & U.K. Under USD2 Billion Index;S&P Developed Ex-U.S. BMI Index;S&P Developed Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Growth Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Europe Under USD2 Billion Index;S&P Developed Ex-Europe Under USD3 Billion Index;S&P Developed Ex-Japan SmallCap Index;S&P Developed Ex-Switzerland BMI Growth Index;S&P Developed Ex-Switzerland BMI Growth Health Care (Sector) Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD1.2 Billion Index;S&P Developed Ex-U.S. Under USD1.5 Billion Index;S&P Developed Under USD1.5 Billion Index;S&P Developed Ex-Japan SmallCap Growth Index;S&P Developed Ex-Switzerland SmallCap Index;S&P Developed Ex-Switzerland SmallCap Growth Index;S&P Developed Ex-Switzerland Under USD1.5 Billion Index;S&P Developed Ex-U.K. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. Under USD2 Billion Index;S&P Developed Ex-U.K. Under USD3 Billion Index;S&P Canada BMI Index;S&P Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. & Japan SmallCap Index;S&P Developed Ex-U.S. & Japan Under USD1 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Index;S&P Canada Under USD1 Billion Index;S&P Developed BMI Growth Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Index;S&P Developed Ex-Asia-Pacific Under USD1 Billion Index;S&P Developed Ex-U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. & Japan SmallCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-U.S. & U.K. BMI Health Care (Sector) Index;S&P Developed Ex-Australia SmallCap Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P Global Ex-Japan Under USD1.5 Billion Index;S&P Global Ex-Japan Under USD2 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. BMI Growth Index;S&P Developed Ex-Japan Under USD3 Billion Index;S&P Developed Ex-Switzerland Under USD1.2 Billion Index;S&P Developed Ex-U.K. BMI Index;S&P Global BMI Index;S&P Global Ex-Japan Under USD3 Billion Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia SmallCap Growth Index;S&P Global Ex-U.S. SmallCap Growth Index;S&P Global SmallCap Health Care (Sector) Index;S&P Developed Ex-U.S. SmallCap Index;S&P Developed Ex-U.S. Under USD2 Billion Index;S&P Developed Under USD2 Billion Index;S&P Global Ex-U.S. SmallCap Health Care (Sector) Index;S&P Global Ex-U.S. Under USD1.2 Billion Index;S&P Global Ex-U.S. Under USD3 Billion Index;S&P Global Under USD2 Billion Index;S&P Global Under USD3 Billion Index;S&P Global SmallCap Index;S&P Global SmallCap Growth Index;S&P North America SmallCap Index;S&P North America SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Index;S&P Global Ex-Japan Under USD1 Billion Index;S&P Global Ex-Japan Under USD1.2 Billion Index;S&P Global Ex-Pan Asia SmallCap Health Care (Sector) Index;S&P Global Ex-Pan Asia Under USD1 Billion Index;S&P Global Ex-Pan Asia Under USD1.5 Billion Index;S&P Global Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. SmallCap Index;S&P Global Ex-U.S. Under USD2 Billion Index;S&P North America BMI Index;S&P Global SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia Under USD1.2 Billion Index;S&P Global Ex-Pan Asia Under USD2 Billion Index;S&P Global Ex-Pan Asia Under USD3 Billion Index;S&P Global Ex-U.S. BMI Index;S&P Global Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-U.S. Under USD1.5 Billion Index;S&P Global Under USD1 Billion Index;S&P Global Under USD1.5 Billion Index;S&P Developed Ex-U.S. & Japan Under USD3 Billion Index;S&P North America SmallCap Growth Health Care (Sector) Index;S&P North America BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America SmallCap Health Care (Sector) Index;S&P North America Under USD1.2 Billion Index;S&P North America Under USD1.5 Billion Index;S&P Developed Ex-U.S. & U.K. SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-U.S. Under USD1 Billion Index;S&P Developed SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Under USD1 Billion Index;S&P North America Under USD2 Billion Index;S&P North America Under USD3 Billion Index;S&P Global BMI Growth Index;S&P Global Ex-Japan BMI Growth Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Japan SmallCap Growth Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia BMI Growth Index;S&P Global Ex-U.S. Under USD1 Billion Index;S&P North America BMI Growth Index;S&P North America BMI Growth Health Care (Sector) Index;S&P North America BMI Health Care (Sector) Index;S&P Canada SmallCap Growth Health Care (Sector) Index;S&P Canada Under USD1.5 Billion Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific SmallCap Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Under USD1.5 Billion Index;S&P Developed Ex-Australia Under USD1.5 Billion Index;S&P Developed Ex-Australia Under USD2 Billion Index;S&P DM Ex-Europe SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Japan BMI Growth Index;S&P Developed Ex-Japan Under USD1.5 Billion Index;S&P Developed Ex-U.K. SmallCap Growth Index;S&P Developed Ex-U.S. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.S. SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed SmallCap Growth Index;S&P Developed SmallCap Growth Health Care (Sector) Index;S&P Developed SmallCap Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global Ex-Japan BMI Index;S&P Global Ex-Japan SmallCap Health Care (Sector) Index;S&P Global Ex-Japan SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia SmallCap Index;S&P Global Under USD1.2 Billion Index;S&P North America SmallCap Growth Index;S&P North America Under USD1 Billion Index;S&P Developed Ex-Japan BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Eurozone BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. & Japan BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Growth Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-UK BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Australia BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-U.S. BMI Growth Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Israel BMI Growth Index;S&P Developed Ex-Israel BMI Growth Health Care (Sector) Index;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel SmallCap Growth Index;S&P Developed Ex-Israel SmallCap Growth Health Care (Sector) Index;S&P Developed Ex-Israel SmallCap Index;S&P Developed Ex-Israel SmallCap Health Care (Sector) Index;S&P DM Ex-Israel SmallCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel Under USD1 Billion Index;S&P Developed Ex-Israel Under USD1.2 Billion Index;S&P Developed Ex-Israel Under USD1.5 Billion Index;S&P Developed Ex-Israel Under USD2 Billion Index;S&P Developed Ex-Israel Under USD3 Billion Index;S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P Developed BMI Ex-U.S. & Korea Index;S&P DM Ex. Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Australia SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group;S&P DM Ex-Israel SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed Ex-U.S. & Japan SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P Developed Ex-U.S. & U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Canada SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia-Pacific SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Subsec;S&P DM Ex-Europe SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Eurozone SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.S. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.K. SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-China A BMI;S&P Global Ex-China A SmallCap;S&P Global Ex-U.S. & China A BMI;S&P Global Ex-U.S. & China A SmallCap;S&P Developed Ex-Korea BMI;S&P Developed Ex-U.S. & Korea SmallCap;S&P Developed Ex-Korea SmallCap;S&P Canada BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK SmallCap Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Growth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & Japan BMI Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. SmallCap Grwth Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland SmallCap Grwth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-U.S. & UK SmallCap Growth Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Growth


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Milestone Pharmaceuticals USA ,Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-15-2023
-
Shelf Registration
Target
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)

RTW Investments, LP
61.11
Apr-28-2023
-
Shelf Registration
Target
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)


9.87
Mar-28-2023
Mar-28-2023
Private Placement
Target
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
RTW Investments, LP

50.00
Mar-24-2022
-
Shelf Registration
Target
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)


14.52
Nov-12-2021
-
Shelf Registration
Target
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)


250.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-12-2023
Company Conference Presentations
Milestone Pharmaceuticals Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-12-2023 09:00 AM
Jun-20-2023
Product-Related Announcements
Milestone Pharmaceuticals Inc. Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in the Lancet
Jun-09-2023
Company Conference Presentations
Milestone Pharmaceuticals Inc. Presents at Jefferies 2023 Global Healthcare Conference, Jun-09-2023 08:30 AM
Jun-07-2023
Annual General Meeting
Milestone Pharmaceuticals Inc., Annual General Meeting, Jun 07, 2023
Jun-07-2023
Shareholder/Analyst Calls
Milestone Pharmaceuticals Inc. - Shareholder/Analyst Call


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
Private Placement Advisors
Cooley LLP, Cowen and Company, LLC
Public Offering Advisors
Cooley LLP, Osler, Hoskin & Harcourt LLP, PricewaterhouseCoopers LLP, PricewaterhouseCoopers LLP, Canada


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
The Economy Matters

Oct 09, 2023 01:32 AM
MIST
The Economy Matters
Reports
8
CFRA Equity Research

Oct 07, 2023 08:43 PM
MIST
Milestone Pharmaceuticals Inc.
Reports
9
S&P Global Compustat

Oct 05, 2023 04:14 AM
MIST
Milestone Pharmaceuticals Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 04:56 AM
MIST
ValuEngine Rating and Forecast Report for MIST
Reports
11
GlobalData

Sep 12, 2023 03:39 AM
MIST
Milestone Pharmaceuticals Inc (MIST.NASD) - Financial Analysis Review
Reports
158
S&P Global Compustat

Sep 07, 2023 04:13 AM
MIST
Milestone Pharmaceuticals Inc 2023_09_07
Reports
14
GlobalData

Aug 23, 2023 06:41 AM
MIST
Milestone Pharmaceuticals Inc (MIST.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
65
H.C. Wainwright & Co.
Trucchio, Patrick Ralph
Aug 14, 2023 08:31 AM
MIST
2Q23 Results; Etripamil for PSVT NDA Submission Expected in October; Phase 2 AFib Data Expected 4Q23; Reiterate Buy
EPS Estimates*
11
Oppenheimer & Co. Inc.
Gershell, Leland James
Aug 10, 2023 08:30 PM
MIST
Reports 2Q, Etripamil's Phase 2 Reveal in AFib-RVR Next Quarter
EPS Estimates*
6
Piper Sandler Companies
Tenthoff, Edward Andrew
Aug 10, 2023 03:31 PM
MIST
Cash of $88M; NDA for Etripamil for PSVT in October; Phase II AFib Data in 4Q23
EPS Estimates*
4


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


RTW Investments, LP

3,256,102

7.58

13.1

Jun-30-2023


BlackRock, Inc.

2,651,200

6.17

10.7

Jun-30-2023


Goldman Sachs Group, Investment Banking and Securities Investments

2,555,287

5.95

10.3

Jun-30-2023


VR Adviser, LLC

2,208,812

5.14

8.9

Jun-30-2023


Millennium Management LLC

1,751,168

4.08

7.0

Jun-30-2023


Bleichroeder LP

1,326,085

3.09

5.3

Jun-30-2023


Alta Fundamental Advisers LLC

897,961

2.09

3.6

Jun-30-2023


Morgan Stanley, Investment Banking and Brokerage Investments

805,039

1.87

3.2

Jun-30-2023


Barclays PLC Private Banking & Investment Banking Investment

800,776

1.86

3.2

Jun-30-2023


Tavistock Life Sciences

698,861

1.63

2.8

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
BlackRock, Inc.
2,651,200
576,842
Affinity Asset Advisors, LLC
300,068
100,686
HANSAINVEST Hanseatische Investment-GmbH
147,276
87,276
BML Capital Management, LLC
272,500
52,500
Squarepoint OPS LLC
45,694
45,694

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Point72 Asset Management, L.P.
245,616
(1,038,304)
Citadel Advisors LLC
469,750
(339,743)
BMO Asset Management Corp.
0
(152,636)
Schonfeld Strategic Advisors LLC
0
(146,806)
JPMorgan Chase & Co, Brokerage and Securities Investments
247,163
(128,891)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Etripamil (Future)


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
Nov-11-2023
Conferences
Nov-11-2023 9:57 AM (EST)
Company Conference Presentations
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-10-2023
-
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEDAR
News Releases
457 KB
Aug-10-2023
Jun-30-2023
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEDAR
Interim Financial Statements
2 MB
Aug-10-2023
Aug-10-2023
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEC
8-K (2.02, 9.01)
301 KB
Aug-10-2023
Jun-30-2023
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEC
10-Q
6 MB
Jun-09-2023
Jun-07-2023
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEC
8-K (5.07, 8.01, 9.01)
234 KB
May-31-2023
-
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEC
424B5
729 KB
May-31-2023
Dec-31-2022
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEC
10-K/A
291 KB
May-15-2023
-
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEC
S-3
474 KB
May-11-2023
Mar-31-2023
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEDAR
Interim Financial Statements
622 KB
May-11-2023
-
Milestone Pharmaceuticals Inc. (NasdaqGS:MIST)
SEDAR
News Releases
417 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Muller, Lorenz  (Former Chief Commercial Officer & Director)
Apr-27-2023
Common Shares
25,000
127,755
Open Market Acquisition
23.07
Multiple
-
Apr-27-2023
Common Shares
7,000
35,396
Open Market Acquisition
-
Exchange Announcement
-
Apr-27-2023
Common Shares
5,500
27,902
Open Market Acquisition
-
Exchange Announcement
-
Apr-27-2023
Common Shares
7,000
36,041
Open Market Acquisition
-
Exchange Announcement
-
Apr-27-2023
Common Shares
5,500
28,416
Open Market Acquisition
-
Exchange Announcement
RTW Investments, LP
Mar-22-2023
Common Shares
(1,059,000)
-
Other Disposition
(24.54)
Form 4
Bharucha FACC, M.D., Ph.D., David B. (Chief Medical Officer)
Dec-01-2022 - Dec-05-2022
Common Shares
10,000
64,484
Open Market Acquisition
New
Form 4
-
Dec-01-2022
Common Shares
3,000
19,831
Open Market Acquisition
-
Form 4
-
Dec-05-2022
Common Shares
7,000
44,653
Open Market Acquisition
-
Form 4
Liebert, Debra K. (Independent Non-Executive Director)
Oct-20-2022 - Oct-21-2022
Common Shares
14,000
100,568
Open Market Acquisition
11,023.62
Form 4
-
Oct-20-2022
Common Shares
10,000
71,951
Open Market Acquisition
-
Form 4
-
Oct-21-2022
Common Shares
4,000
28,617
Open Market Acquisition
-
Form 4
Pasternak M.D., Richard C. (Independent Non-Executive Director)
Oct-20-2022
Common Shares
10,000
70,727
Open Market Acquisition
New
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Wills, Robert James
Independent Chairman of the Board
514 336 0444
-

Oliveto, Joseph G.
CEO, President & Director
(514) 336-0444
-

Douville, Philippe 
Founder, Strategic Advisor & Member of Scientific Advisory Board
514 336 0444
-
pdouville@findtherapeutics.com
Sager, Philip T.
Chief Medical Advisor & Member of the Scientific Advisory Board
514 336 0444
-

Liebert, Debra K.
Independent Non-Executive Director
514 336 0444
-
Liebert@domainvc.com
Tomsicek, Michael John
Independent Non-Executive Director
514 336 0444
-

Camm, John 
Member of the Scientific Advisory Board
514 336 0444
-

DiMarco, John
Member of the Scientific Advisory Board
514 336 0444
-
-
Dorian, Paul 
Member of the Scientific Advisory Board
514 336 0444
-

Fischer, Seth H. Z.
Independent Non-Executive Director
514 336 0444
-

Giles, Lisa M.
Independent Non-Executive Director
514 336 0444
-

Kopelman, Harry A.
Member of the Scientific Advisory Board
514 336 0444
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Oliveto, Joseph G.
CEO, President & Director
(514) 336-0444
-

Douville, Philippe 
Founder, Strategic Advisor & Member of Scientific Advisory Board
514 336 0444
-
pdouville@findtherapeutics.com
Hasija, Amit 
CFO & Executive VP of Corporate Development
514 336 0444
-

Nelson, Jeff 
Chief Operating Officer
514 336 0444
-

Fox, Kim 
Vice President of Communications
514 336 0444
-

Girglani, Roshan 
Vice President of Marketing
514 336 0444
-

Bharucha, David B.
Chief Medical Officer
514 336 0444
-

Holz, Anita 
VP & Head of Medical Affairs
514 336 0444
-

Rousseau, Guy 
SVP of Regulatory Affairs and Quality Management
514 336 0444
-

Sager, Philip T.
Chief Medical Advisor & Member of the Scientific Advisory Board
514 336 0444
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
